Cargando…
Minibody-Based and scFv-Based Antibody Fragment-Drug Conjugates Selectively Eliminate GD2-Positive Tumor Cells
Ganglioside GD2 is a well-established target expressed on multiple solid tumors, many of which are characterized by low treatment efficiency. Antibody-drug conjugates (ADCs) have demonstrated marked success in a number of solid tumors, and GD2-directed drug conjugates may also hold strong therapeuti...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9860947/ https://www.ncbi.nlm.nih.gov/pubmed/36674755 http://dx.doi.org/10.3390/ijms24021239 |
_version_ | 1784874718562615296 |
---|---|
author | Kalinovsky, Daniel V. Kholodenko, Irina V. Kibardin, Alexey V. Doronin, Igor I. Svirshchevskaya, Elena V. Ryazantsev, Dmitriy Y. Konovalova, Maria V. Rozov, Fedor N. Larin, Sergey S. Deyev, Sergey M. Kholodenko, Roman V. |
author_facet | Kalinovsky, Daniel V. Kholodenko, Irina V. Kibardin, Alexey V. Doronin, Igor I. Svirshchevskaya, Elena V. Ryazantsev, Dmitriy Y. Konovalova, Maria V. Rozov, Fedor N. Larin, Sergey S. Deyev, Sergey M. Kholodenko, Roman V. |
author_sort | Kalinovsky, Daniel V. |
collection | PubMed |
description | Ganglioside GD2 is a well-established target expressed on multiple solid tumors, many of which are characterized by low treatment efficiency. Antibody-drug conjugates (ADCs) have demonstrated marked success in a number of solid tumors, and GD2-directed drug conjugates may also hold strong therapeutic potential. In a recent study, we showed that ADCs based on the approved antibody dinutuximab and the drugs monomethyl auristatin E (MMAE) or F (MMAF) manifested potent and selective cytotoxicity in a panel of tumor cell lines and strongly inhibited solid tumor growth in GD2-positive mouse cancer models. Here, we employed two different GD2-binding moieties–minibodies and scFv fragments that carry variable antibody domains identical to those of dinutuximab, and site-directly conjugated them to MMAE or MMAF by thiol-maleimide chemistry with drug-to-antibody ratios (DAR) of 2 and 1, respectively. Specific binding of the antibody fragment-drug conjugates (FDCs) to GD2 was confirmed in direct ELISA, flow cytometry, and confocal microscopy. Selective cytotoxic and cytostatic effects of the conjugates were observed in GD2-positive but not GD2-negative neuroblastoma and melanoma cell lines. Minibody-based FDCs demonstrated more pronounced cytotoxic effects and stronger antigen binding compared to scFv-based FDCs. The developed molecules may offer considerable practical benefit, since antibody fragment-drug conjugates are capable of enhancing therapeutic efficacy of ADCs by improving their pharmacokinetic characteristics and reducing side effects. |
format | Online Article Text |
id | pubmed-9860947 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-98609472023-01-22 Minibody-Based and scFv-Based Antibody Fragment-Drug Conjugates Selectively Eliminate GD2-Positive Tumor Cells Kalinovsky, Daniel V. Kholodenko, Irina V. Kibardin, Alexey V. Doronin, Igor I. Svirshchevskaya, Elena V. Ryazantsev, Dmitriy Y. Konovalova, Maria V. Rozov, Fedor N. Larin, Sergey S. Deyev, Sergey M. Kholodenko, Roman V. Int J Mol Sci Article Ganglioside GD2 is a well-established target expressed on multiple solid tumors, many of which are characterized by low treatment efficiency. Antibody-drug conjugates (ADCs) have demonstrated marked success in a number of solid tumors, and GD2-directed drug conjugates may also hold strong therapeutic potential. In a recent study, we showed that ADCs based on the approved antibody dinutuximab and the drugs monomethyl auristatin E (MMAE) or F (MMAF) manifested potent and selective cytotoxicity in a panel of tumor cell lines and strongly inhibited solid tumor growth in GD2-positive mouse cancer models. Here, we employed two different GD2-binding moieties–minibodies and scFv fragments that carry variable antibody domains identical to those of dinutuximab, and site-directly conjugated them to MMAE or MMAF by thiol-maleimide chemistry with drug-to-antibody ratios (DAR) of 2 and 1, respectively. Specific binding of the antibody fragment-drug conjugates (FDCs) to GD2 was confirmed in direct ELISA, flow cytometry, and confocal microscopy. Selective cytotoxic and cytostatic effects of the conjugates were observed in GD2-positive but not GD2-negative neuroblastoma and melanoma cell lines. Minibody-based FDCs demonstrated more pronounced cytotoxic effects and stronger antigen binding compared to scFv-based FDCs. The developed molecules may offer considerable practical benefit, since antibody fragment-drug conjugates are capable of enhancing therapeutic efficacy of ADCs by improving their pharmacokinetic characteristics and reducing side effects. MDPI 2023-01-08 /pmc/articles/PMC9860947/ /pubmed/36674755 http://dx.doi.org/10.3390/ijms24021239 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Kalinovsky, Daniel V. Kholodenko, Irina V. Kibardin, Alexey V. Doronin, Igor I. Svirshchevskaya, Elena V. Ryazantsev, Dmitriy Y. Konovalova, Maria V. Rozov, Fedor N. Larin, Sergey S. Deyev, Sergey M. Kholodenko, Roman V. Minibody-Based and scFv-Based Antibody Fragment-Drug Conjugates Selectively Eliminate GD2-Positive Tumor Cells |
title | Minibody-Based and scFv-Based Antibody Fragment-Drug Conjugates Selectively Eliminate GD2-Positive Tumor Cells |
title_full | Minibody-Based and scFv-Based Antibody Fragment-Drug Conjugates Selectively Eliminate GD2-Positive Tumor Cells |
title_fullStr | Minibody-Based and scFv-Based Antibody Fragment-Drug Conjugates Selectively Eliminate GD2-Positive Tumor Cells |
title_full_unstemmed | Minibody-Based and scFv-Based Antibody Fragment-Drug Conjugates Selectively Eliminate GD2-Positive Tumor Cells |
title_short | Minibody-Based and scFv-Based Antibody Fragment-Drug Conjugates Selectively Eliminate GD2-Positive Tumor Cells |
title_sort | minibody-based and scfv-based antibody fragment-drug conjugates selectively eliminate gd2-positive tumor cells |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9860947/ https://www.ncbi.nlm.nih.gov/pubmed/36674755 http://dx.doi.org/10.3390/ijms24021239 |
work_keys_str_mv | AT kalinovskydanielv minibodybasedandscfvbasedantibodyfragmentdrugconjugatesselectivelyeliminategd2positivetumorcells AT kholodenkoirinav minibodybasedandscfvbasedantibodyfragmentdrugconjugatesselectivelyeliminategd2positivetumorcells AT kibardinalexeyv minibodybasedandscfvbasedantibodyfragmentdrugconjugatesselectivelyeliminategd2positivetumorcells AT doroninigori minibodybasedandscfvbasedantibodyfragmentdrugconjugatesselectivelyeliminategd2positivetumorcells AT svirshchevskayaelenav minibodybasedandscfvbasedantibodyfragmentdrugconjugatesselectivelyeliminategd2positivetumorcells AT ryazantsevdmitriyy minibodybasedandscfvbasedantibodyfragmentdrugconjugatesselectivelyeliminategd2positivetumorcells AT konovalovamariav minibodybasedandscfvbasedantibodyfragmentdrugconjugatesselectivelyeliminategd2positivetumorcells AT rozovfedorn minibodybasedandscfvbasedantibodyfragmentdrugconjugatesselectivelyeliminategd2positivetumorcells AT larinsergeys minibodybasedandscfvbasedantibodyfragmentdrugconjugatesselectivelyeliminategd2positivetumorcells AT deyevsergeym minibodybasedandscfvbasedantibodyfragmentdrugconjugatesselectivelyeliminategd2positivetumorcells AT kholodenkoromanv minibodybasedandscfvbasedantibodyfragmentdrugconjugatesselectivelyeliminategd2positivetumorcells |